Xcout Intel
QureTech Bio
QureTech Bio is a biotechnology company that develops treatments to defeat bacterial virulence and restore antibiotic susceptibility, specifically targeting drug-resistant infections such as Staphylococcus aureus. The company serves the pharmaceutical and healthcare sectors by advancing novel antibacterial portfolios and seeking partnership opportunities.
Subscribe to see QureTech Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
QureTech Bio at a glance
QureTech Bio is a biotechnology, drug discovery company headquartered in Sweden. Xcout tracks 9 named people at QureTech Bio, including Markus Thor (CEO).
QureTech Bio leadership
- Markus ThorCEO
- Annica RönnbäckCOO
- Lennart HanssonCHAIRMAN
- Fredrik AlmqvistBOARD MEMBER
- Scott HultgrenBOARD MEMBER
- Erik GozziBOARD MEMBER
3 more named people on record for QureTech Bio, with roles, board committees and tenure — see the full roster →
QureTech Bio competitors
A few of QureTech Bio's closest competitors — see the full list of competitors and alternatives →
Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company based in Oklahoma City, Oklahoma, developing orally active compounds that restore the efficacy of existing antibiotics.
Recreo Pharmaceuticals LLC is a healthcare company focused on developing and testing antibiotics to combat antibiotic resistance and improve patient health. The firm monitors industry trends and medical technology to advance its drug development initiatives.
Paratek Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for complex medical conditions, focusing on infectious diseases and antimicrobial resistance. The company's product portfolio includes NUZYRA, an antibiotic for bacterial infections, and XHANCE, a nasal spray for chronic rhinosinusitis. These treatments are designed to serve adult patients with significant unmet medical needs.
Shanghai MicuRx Pharmaceutical Co., Ltd. is a China-based biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections, including drug-resistant infections. It developed contezolid (MRX-I), an oxazolidinone antibiotic intended for treatment of resistant Gram-positive bacterial infections, serving hospitals and infectious-disease patients.
Quest PharmaTech Inc. is a Canadian pharmaceutical company that develops products for targeted cancer therapy, including proprietary antibodies. The company operates and invests in various biotechnology ventures, holding ownership interests in firms focused on advancing immunotherapy treatments.
AiCuris Anti-infective Cures AG is a biopharmaceutical company headquartered in Wuppertal, Germany. The company specializes in the research and development of innovative, life-saving anti-infective therapies designed to address critical needs in immunocompromised patients.
Get QureTech Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on QureTech Bio in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access